Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Mallinckrodt
Harvard Business School
Medtronic
Baxter

Last Updated: January 27, 2023

Investigational Drug Information for PF-06463922


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug PF-06463922?

PF-06463922 is an investigational drug.

There have been 16 clinical trials for PF-06463922. The most recent clinical trial was a Phase 1 trial, which was initiated on December 31st 2021.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Lymphoma. The leading clinical trial sponsors are Pfizer, Clinical research technology Srl, and Fondazione Ricerca Traslazionale.

There are twenty-one US patents protecting this investigational drug and two hundred and ninety-eight international patents.

Recent Clinical Trials for PF-06463922
TitleSponsorPhase
Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of LorlatinibPfizerPhase 1
Lorlatinib Continuation StudyPfizerPhase 4
PF-07284892 in Participants With Advanced Solid TumorsPfizerPhase 1

See all PF-06463922 clinical trials

Clinical Trial Summary for PF-06463922

Top disease conditions for PF-06463922
Top clinical trial sponsors for PF-06463922

See all PF-06463922 clinical trials

US Patents for PF-06463922

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-06463922 See Plans and Pricing Substituted macrocycles useful as kinases inhibitors and methods of use thereof Teligene Ltd. (Suzhou, CN) See Plans and Pricing
PF-06463922 See Plans and Pricing Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) See Plans and Pricing
PF-06463922 See Plans and Pricing CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) See Plans and Pricing
PF-06463922 See Plans and Pricing Treatment of cancer using anti-CD19 Chimeric Antigen Receptor The Trustees of the University of Pennsylvania (Philadelphia, PA) Novartis AG (Basel, CH) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-06463922

Drugname Country Document Number Estimated Expiration Related US Patent
PF-06463922 China CN107207528 2034-08-20 See Plans and Pricing
PF-06463922 European Patent Office EP3183256 2034-08-20 See Plans and Pricing
PF-06463922 Japan JP2017525716 2034-08-20 See Plans and Pricing
PF-06463922 Japan JP6609308 2034-08-20 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Mallinckrodt
Harvard Business School
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.